Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07557654

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT

The goal of this observational study is to evaluate the feasibility and effectiveness of using non-contrast chest computed tomography scans for opportunistic breast cancer screening, and to further compare its diagnostic performance with conventional imaging modalities, including mammography and/or breast magnetic resonance imaging.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

About this study

Breast cancer is one of the most common malignancies in women, and early detection is essential for improving clinical outcomes. While dedicated breast imaging modalities, including mammography and breast MRI, are widely used for screening. Many women undergo non-contrast chest CT scans for other clinical indications, providing a potential opportunity for breast evaluation. This observational study aims to investigate the clinical value of non-contrast chest CT scans as an opportunistic screening tool for breast cancer. Breast tissue visible on routine CT scans will be assessed using artificial intelligence-based methods to identify suspicious lesions. The primary objective is to evaluate the diagnostic performance of non-contrast chest CT in detecting breast cancer, including sensitivity, specificity, and accuracy, and to further compare its diagnostic performance with mammography and breast MRI. The findings are expected to determine whether non-contrast chest CT can serve as an opportunistic tool for early breast cancer detection without additional imaging burden, and to clarify its relative clinical value compared with established breast imaging techniques.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients who have undergone non-contrast chest CT examination;
  • Participants included in the comparative analysis must have undergone at least one comparator imaging modality (mammography and/or breast MRI);
  • If a breast lesion is detected, it must be confirmed by pathology or clinical follow-up at least 12 months;
  • No prior systemic or local therapy before imaging examinations;
  • Imaging data are complete and of sufficient quality for analysis.

Exclusion criteria

  • History of other malignancies with potential impact on breast imaging interpretation;
  • Participants with suspected malignant breast lesions but no confirmation;
  • Prior radiotherapy, chemotherapy, or immunotherapy before imaging examinations;
  • Imaging data that are incomplete, of poor quality, or contain significant artifacts preventing reliable analysis;
  • Time interval between non-contrast chest CT and comparator imaging modalities exceeding three months, or with clinical events occurring between examinations that may alter lesion status.

Treatment and study plan

Primary outcomes

  1. Screening performance of non-contrast chest CT for detection of breast cancer, with comparison to mammography and/or breast MRI

    Time frame: Up to 12 months

    The primary outcome is the screening performance of AI-assisted analysis for the detection of breast cancer on non-contrast chest CT. The detection process is conducted in a stepwise approach, involving lesion identification followed by classification into benign or malignant categories for breast cancer detection. Performance metrics include sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and area under the receiver operating characteristic curve. Participants included in the comparative analysis must have undergone at least one comparator imaging modality (mammography and/or breast MRI) within three months of the chest CT examination, with no intervening clinical events. Performance metrics will be further compared with those obtained from mammography and/or breast MRI within the same participants to evaluate the relative screening performance.

Secondary outcomes

  1. Performance of non-contrast chest CT for histological classification of breast cancer, with comparison to mammography and/or breast MRI

    Time frame: Up to 12 months

    The secondary outcome is the performance of AI-assisted analysis for classifying the histological types of breast cancer on non-contrast chest CT. Histological types are defined according to the World Health Organization classification system based on histopathological examination. Performance metrics include sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and area under the receiver operating characteristic curve. Participants included in the comparative analysis must have undergone at least one comparator imaging modality (mammography and/or breast MRI) within three months of the chest CT examination, with no intervening clinical events. Performance metrics will be further compared with those obtained from mammography and/or breast MRI within the same participants to evaluate the relative classification performance.

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Artificial Intelligence-Assisted Opportunistic Screening for Breast Cancer Using Non-Contrast Chest CT: A Comparative Study With Mammography and/or Breast MRI

Acronym: OPBCS-CT

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Apr 29, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.